Buy now (pre-market momentum setup): Trend structure is bullish (SMA_5 > SMA_20 > SMA_200) and price is pushing higher pre-market (+4.5% to ~2.32), which fits an impatient, momentum-first approach.
Near-term roadmap: First upside test is R1 ~2.50; if it clears, next is R2 ~2.75. Key nearby support is pivot ~2.09.
Why still buy without signals: Options positioning is extremely call-heavy (very low put/call), and the technicals remain constructive; the main risk is that the stock is approaching resistance where pullbacks can happen quickly.
Technical Analysis
Trend: Bullish moving average stack (SMA_5 > SMA_20 > SMA_200) suggests an established uptrend.
MACD: Histogram +0.0355 (above zero) but positively contracting → upside momentum is still present but not accelerating.
RSI (6): ~60.7 (neutral-to-slightly-bullish), not overheated; room to push but not a “fresh breakout” reading.
Key levels:
Pivot: 2.094 (important hold area)
Resistance: 2.502 (R1) then 2.753 (R2)
Support: 1.687 (S1) then 1.436 (S2)
Pattern-based short-term odds (provided): Mild negative bias (about -0.81% next day / -0.43% next week) despite bullish trend—supports the idea that resistance around 2.50 may be “sticky.”
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment (positioning): Open interest put/call 0.03 is extremely low → market positioning is heavily call-skewed / bullish.
Volume skew: Put volume reported as 0 with call volume 113 → trading flow is one-sided bullish in the snapshot.
Implied volatility: IV30 ~240% with IV percentile ~92.8 → options are pricing large moves; sentiment is hot, but options are expensive (often seen around biotech/catalyst names).
Activity vs average: Today’s volume vs 30D avg ~63% (not a blowout), suggesting bullish skew is more structural (OI) than a single-day frenzy.
Technical Summary
Sell
2
Buy
7
Positive Catalysts
Analyst initiation with large upside: Oppenheimer initiated Outperform with $10 PT (vs ~$2.2–$2.3 area), explicitly tied to 2026 clinical readouts and platform pipeline optimism.
Pipeline narrative: Interest around tagmokitug (anti-CCR8) in combination with Loqtorzi (PD-1 backbone) plus casdozokitug (anti-IL-27) as a differentiated early-stage asset.
Financial trend improvement (QoQ/YoY snapshot): Revenue up sharply YoY and losses narrowing materially (see financial section), which can improve sentiment in small-cap biotech/oncology names.
Upcoming event: Next earnings on 2026-03-03 (after hours) can act as a volatility catalyst.
Neutral/Negative Catalysts
and R1 (2.502); failed attempts at R1 can lead to quick pullbacks.
Financial Performance
Latest quarter (2025/Q3):
Revenue: $11.57M, +91.19% YoY (strong top-line growth off a small base).
Net income: - $35.53M, improved +230.49% YoY (still a loss, but materially less negative than prior year).
Gross margin: 67.84%, +23.55% YoY (improving unit economics / mix).
Takeaway: Clear YoY improvement trend (growth + narrowing losses), but profitability is not yet achieved and future results may be catalyst-dependent (pipeline/earnings updates).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent rating/target trend: Limited coverage updates provided; the notable change is a new initiation.
Thesis anchored to 2026 clinical readouts and the strategy of pairing tagmokitug with a commercial PD-1 backbone (Loqtorzi).
Additional optionality from casdozokitug (anti-IL-27).
Wall Street con view (bear case):
Execution and clinical-readout timing risk (value heavily dependent on future data).
Small-cap biotech volatility and funding/operational uncertainty (noted indirectly by persistent losses).
Influential/political trading check: No recent congress trading data available; hedge funds and insiders shown as neutral with no significant recent trend.
Wall Street analysts forecast CHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHRS is 5.5 USD with a low forecast of 4 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHRS is 5.5 USD with a low forecast of 4 USD and a high forecast of 7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.090
Low
4
Averages
5.5
High
7
Current: 2.090
Low
4
Averages
5.5
High
7
Oppenheimer
NULL -> Outperform
initiated
$10
AI Analysis
2026-01-22
Reason
Oppenheimer
Price Target
$10
AI Analysis
2026-01-22
initiated
NULL -> Outperform
Reason
Oppenheimer initiated coverage of Coherus Oncology with an Outperform rating and $10 price target.
Oppenheimer
Jay Olson
Outperform
initiated
$10
2026-01-22
Reason
Oppenheimer
Jay Olson
Price Target
$10
2026-01-22
initiated
Outperform
Reason
As previously reported, Oppenheimer analyst Jay Olson initiated coverage of Coherus Oncology with an Outperform rating and $10 price target, citing upcoming clinical readouts in 2026 across multiple cancers for lead anti-CCR8 antibody tagmokitug combined with in-licensed, commercial PD-1 backbone Loqtorzi. Additionally, the firm thinks casdozokitug, Coherus' "only-in-class" anti-IL-27 antibody, represents "a high-potential early-stage opportunity," the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CHRS
